Skip to main content
Figure 6 | Cardiovascular Diabetology

Figure 6

From: Glibenclamide attenuates myocardial injury by lipopolysaccharides in streptozotocin-induced diabetic mice

Figure 6

Glibenclamide inhibited serum IL-1β and TNF-α levels by LPS stimulation in streptozotocin (STZ) diabetic mice. Serum IL-1β and TNF-α levels were assessed by ELISA 6 h after LPS injection (15 mg/kg, i.p). In non-STZ treated mice, LPS stimulation significantly increased both IL-1β and TNF-α levels. In STZ treated mice, LPS stimulation induced greater levels of IL-1β and TNF-α than those in non-STZ treated ones, which were significantly inhibited by glibenclamide (5 mg/kg, i.g, × 14 d) pretreatment. *P < 0.05, **P < 0.01 vs control; #P < 0.05, ##P < 0.01 vs STZ + LPS, †P < 0.05 vs LPS. Values are means ± SEM (n = 8-10 per group).

Back to article page